Xenetic Biosciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference

LEXINGTON, Mass.–(BUSINESS WIRE)– Xenetic
Biosciences, Inc. (OTCQB: XBIO) (“Xenetic” or the “Company”), a
biopharmaceutical company developing next-generation biologic drugs and
novel orphan oncology therapeutics, today announced that Scott
Maguire, CEO of Xenetic Biosciences, will present at the Ladenburg
Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016 at
3:30 p.m. ET in New York at the Sofitel New York.

During his presentation, Mr. Maguire will provide a corporate update and
discuss the Company’s clinical and regulatory strategies for its product
candidates currently in development in-house and with Xenetic’s
biotechnology and pharmaceutical partners.
The Company’s product pipeline currently includes Virexxa®
(sodium cridanimod), which is being evaluated for the treatment of
endometrial cancer and triple negative breast cancer, ErepoXen™,
a polysialylated form of erythropoietin (EPO), a hormone produced by the
kidneys to maintain red blood cell production and prevent anemia, and OncoHist™,
which is being evaluated for the treatment of acute myeloid leukemia
(AML) in refractory patients and refractory non-Hodgkin lymphoma (NHL).

Mr. Maguire will also discuss Xenetic’s $100 million license deal with Shire
and provide an overview of the product candidate and clinical status.

A live webcast of the presentation will be available by accessing the IR
Calendar in the Investors
section of the Xenetic website (www.xeneticbio.com).
The webcast replay will be available approximately two hours after the
presentation ends and will be accessible for 90 days.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company developing
next-generation biologic drugs and novel oncology therapeutics.
Xenetic’s proprietary drug technology platforms include PolyXen™,
designed to develop next generation biologic drugs by extending the
efficacy, safety and half-life of biologic drugs.

Xenetic’s lead product candidates include ErepoXen™, a polysialylated
form of erythropoietin for the treatment of anemia in pre-dialysis
patients with chronic kidney disease, and FDA orphan designated oncology
therapeutics Virexxa™ and Oncohist™ for the treatment of progesterone
receptor negative endometrial cancer and refractory Acute Myeloid
Leukemia.

Xenetic is also working together with Shire plc (formerly Baxalta
Incorporated and Baxter Healthcare) to develop a novel series of
polysialylated blood coagulation factors, including a next generation
Factor VIII. This collaboration relies on Xenetic’s PolyXen technology
to conjugate polysialic acid (“PSA”) to therapeutic blood-clotting
factors, with the goal of improving the pharmacokinetic profile and
extending the active life of these biologic molecules. Shire is one of
the Company’s largest shareholders having invested $10M in the common
stock of the Company during 2014. The agreement is an exclusive
research, development and license agreement which grants Shire a
worldwide, exclusive, royalty-bearing license to Xenetic’s PSA patented
and proprietary technology in combination with Shire’s proprietary
molecules designed for the treatment of blood and bleeding disorders.
Under the agreement, Xenetic may receive regulatory and sales target
payments for total potential milestone receipts of up to $100
million plus royalties on sales.

Xenetic is also developing a broad pipeline of clinical candidates for
next generation biologics and novel oncology therapeutics in a number of
orphan disease indications. For more information, please visit the
company’s website at www.xeneticbio.com and
connect on Twitter, LinkedIn, Facebook and Google+.

Forward-Looking Statements

This press release contains « forward-looking statements, » as that term
is defined under the Private Securities Litigation Reform Act of 1995
(PSLRA), which statements may be identified by words such as « expects, »
« plans, » « projects, » « will, » « may, » « anticipates, » « believes, » « should, »
« intends, » « estimates, » and other words of similar meaning, including
statements regarding expected benefits of NGS cancer panels, the ability
to accurately determine the heritable factors increasing the risk of
cancer, permitting tailored treatment, screening and prevention of
cancer in patients, as well as other non-historical statements about our
expectations, beliefs or intentions regarding our business, technologies
and products, financial condition, strategies or prospects. Many factors
could cause our actual activities or results to differ materially from
the activities and results anticipated in forward-looking statements.
These factors include those described in our filings with the Securities
and Exchange Commission, as well as the risks inherent in funding,
developing and obtaining regulatory approvals of new,
commercially-viable and competitive products and treatments. In
addition, forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press release
speak only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We intend
that all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160922005348/en/